Oral nutrition supplements and between-meal snacks for nutrition therapy in patients with COPD identified as at nutritional risk: a randomised feasibility trial

Arora Ros Ingadottir,^{1,2} Anne Marie Beck,^{3,4} Christine Baldwin,⁵ Christine Elizabeth Weekes,⁵ Olof Gudny Geirsdottir,^{1,6} Alfons Ramel,¹ Thorarinn Gislason,^{7,8} Ingibjorg Gunnarsdottir^{1,2}

To cite: Ingadottir AR, Beck AM, Baldwin C, *et al.* Oral nutrition supplements and between-meal snacks for nutrition therapy in patients with COPD identified as at nutritional risk: a randomised feasibility trial. *BMJ Open Resp Res* 2019;**6**:e000349. doi:10.1136/bmjresp-2018-000349

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjresp-2018-000349>).

Received 21 August 2018
Revised 7 November 2018
Accepted 27 November 2018

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Arora Ros Ingadottir; aroraros@ish.is

ABSTRACT

Introduction Intervention studies have mainly used oral nutritional supplements (ONS) for the management of patients with chronic obstructive pulmonary disease (COPD) identified as at nutritional risk. In this 12-month randomised feasibility trial, we assessed the (1) feasibility of the recruitment, retention and provision of two interventions: ONS and between-meal snacks (snacks) and (2) the potential impact of the provision of snacks and ONS on body weight and quality of life in patients with COPD.

Methods Hospitalised patients with COPD, at nutritional risk, were randomised to ONS (n=19) or snacks (n=15) providing 600 kcal and 22 g protein a day in addition to regular daily diet. The intervention started in hospital and was continued for 12 months after discharge from the hospital.

Results Study recruitment rate was n=34 (45%) and retention rate at 12 months was similar for both groups: n=13 (68%) in the ONS group and n=10 (67%) in the Snacks group. Both groups gained weight from baseline to 12 months (2.3 ± 4.6 kg ($p=0.060$) in the ONS group and 4.4 ± 6.4 kg ($p=0.030$) in the Snacks group). The St George's Respiratory Questionnaire total score improved from baseline to 12 months in both groups (score 3.9 ± 11.0 ($p=0.176$) in the ONS group and score 8.9 ± 14.1 ($p=0.041$) in the Snacks group).

Discussion In patients with COPD who are at nutritional risk snacks are at least as feasible and effective as ONS, however, adequately powered trials that take account of the difficulties in recruiting this patient group are required to confirm this effect.

INTRODUCTION

Malnutrition is common in patients with chronic obstructive pulmonary disease (COPD)^{1 2} with reported prevalence rates between 20% and 45% depending on the characteristics of the COPD population, and screening tools and cut-off criteria used.^{1–3} Malnutrition in patients with COPD is

Key messages

- Are between-meal snacks and oral nutritional supplements (ONS) feasible and effective on weight change and quality of life (QoL) in hospitalised patients at nutritional risk?
- Both groups gained weight of more than 2 kg from baseline to 12 months and QoL significantly improved from baseline to 3 months in both groups, and improvements from baseline to 12 months were of clinically relevant difference in both groups.
- Our findings imply that snacks are at least as feasible and effective as ONS and were associated in greater improvements in QoL, however, future trials should be informed by the recruitment and retention issues that have been raised and practical issues of undertaken functional measures in this population merits further consideration.

associated with an increased risk of complications, longer hospital stays and increased mortality,^{4–7} leading to an increased economic and operational burden for health services.⁸

Many randomised trials, summarised in systematic reviews, have investigated nutritional interventions to treat malnutrition in patients with stable COPD.^{9–11} Most of the included studies have demonstrated a positive impact on survival, complication rate, length of stay (LOS) and hospital readmissions as well as some nutritional and patient-centred outcomes.^{9–11} However, the evidence for benefit comes mainly from studies using oral nutritional supplements (ONS) and often comparing ONS to a control group receiving no nutritional intervention.^{9–11}

Since the arrival of 'ready-to-use' ONS, the use of food-based strategies seems to have

declined¹² and data on patient-relevant outcomes are lacking.^{12 13} There are also significant financial and practical differences associated with ONS and snacks, which, in the absence of clear evidence to inform decisions, have influenced choice of supplementation method.

In order to investigate the potential role of energy and protein-dense food for patients with COPD, the aims of this 12-month randomised intervention trial were to study the (1) feasibility of the recruitment, retention and provision of each intervention, and (2) the potential impact of the provision of snacks and ONS on body weight, and (3) quality of life (QoL) in patients with COPD.

METHODS

Study design and participants

This study was a randomised trial and registered at ClinicalTrials.gov on 25 September 2014 (ClinicalTrials.gov identifier: NCT02251496). The study was conducted in line with the Declaration of Helsinki. The study follows the Consolidated Standards of Reporting Trials 2010 statement: extension to randomised pilot and feasibility trials.¹⁴

Patients with a clinical diagnosis of COPD who had been recently admitted to the Department of Respiratory Medicine at Landspítali University Hospital were screened for possible nutritional risk (score ≥ 4) by a trained researcher using a validated nutritional screening tool.^{3 15} The Icelandic Simple Screening (ISS) used is recommended by the clinical guidelines for hospital nutrition at Landspítali,¹⁶ and has been validated against a full nutritional assessment in patients with COPD³ and predicts mortality in patients with COPD.¹⁵ ISS gathers information on body mass index (BMI), unintentional weight loss, age, comorbidities, recent hospitalisation and a range of symptoms that impact nutritional intake during the last weeks or months (vomiting, diarrhoea, loss of appetite or nausea, difficulties in chewing or swallowing).

All eligible patients who were able to eat orally, and had an anticipated length of hospitalisation of >3 days were invited to participate in the study. The most common reason for admission was acute exacerbation of COPD. Written informed consent was obtained from all participants.

Patients diagnosed with cancer, dysphagia, food allergy or intolerance and anatomical obstructions preventing oral food intake were excluded. Patients not able to sign informed consent due to cognitive issues were also excluded.

Sociodemographic data (age, gender and smoking status) were collected from electronic medical records SAGA (TM software V.3.1.39.9).

Randomisation and masking

Eligible patients were randomly assigned in a 1:1 ratio to either an ONS group (ONS) or Snacks group. Random sequence generation was performed using

randomisation codes produced by Microsoft Excel for Windows 2007. Randomisation, allocation of patients to groups, nutritional intervention and outcome assessments were performed by one researcher (ARI). Due to the nature of the intervention it was not possible to perform a blinded study. Randomisation took place after screening for nutritional risk and prior to baseline assessment.

Procedures

This study was originally designed as a randomised trial to investigate the effects of snacks on body weight and QoL in patients with COPD compared with ONS with a planned enrolment of 200 subjects (ClinicalTrials.gov, number NCT02251496). Despite screening 492 subjects, only 76 were eligible indicating that recruitment is challenging in this population and clinical setting. Recruitment rates were lower than expected which led to a change in the study protocol to a randomised feasibility trial as funding was limited to 3 years. One reason for low recruitment rates might be overstrict inclusion criteria. More details on study recruitment are provided in the Results section.

Nutritional screening was undertaken on admission using the validated screening tool as recommended for use at the Landspítali.^{3 15 16} A total score of ≥ 4 is considered 'at nutritional risk'.

After providing informed consent, subjects were randomly allocated to one of two groups. Subjects in group 1 were provided with ONS and subjects in group 2 were provided with snacks (table 1). The intervention started in hospital and was continued for 12 months after discharge from the hospital.

Subjects in group 1 were offered a variety of flavours and pack sizes of ONS free of charge. As the hospital had a contract with Nutricia (Icepharma, Iceland) that was the brand used. Subjects in group 2 were provided with snacks free of charge, based on common Icelandic food products, for example, Icelandic skyr which is a high-protein milk product similar to yogurt. Patients in both groups were encouraged to consume two or more ONS or snacks daily providing approximately 600 kcal/day and approximately 22 g protein/day in addition to regular food depending on which group they were in.^{10 11}

The selected ONS were delivered to the patient's home or picked up at the wholesaler and the food packages were delivered to patient's home or collected from the hospital, according to patient's preference. It was assumed that each delivery of ONS and snacks would last for 1 month and 2–3 weeks, respectively. A leaflet designed for this study was provided with pictures of different ONS or each snack and written advice regarding their use such as suggestions on timing of intake, choosing a lower volume (125 mL each) when appetite was poor (ONS) and choice of different meals (snacks). For some items, patients had to portion the

Table 1 Nutritional content of each intervention product

Product	Portion size	Energy (kcal)	Protein (g)
Oral nutritional supplement drinks			
Nutridrink compact (Nutricia) For example, vanilla, banana, strawberry and chocolate	125 mL	300	12
Nutridrink compact fibre (Nutricia) – vanilla, strawberry and mokka	125 mL	300	12
Nutridrink (Nutricia) – vanilla, strawberry, banana and chocolate	200 mL	300	12
Nutridrink juice style (Nutricia) For example, blackcurrant, apple and orange	200 mL	300	8
Nutridrink Creme (Nutricia) – forest fruit and chocolate	125 g	200	12
Mean		280	11
In-between-meal snack			
Blueberry skyr with cream (MS Dairies)	Skyr 140 g Cream 20 mL	254	17
Two mini skyr with cream (MS Dairies) – vanilla, strawberry and banana	Skyr 167 g Cream 20 mL	274	16
Rye bread (Myllan) with liver paté (Ora) and butter (MS Dairies)	Rye bread 55 g Liver paté 40 g Butter 10 g	313	7
Pan bread (Myllan) with ham and egg salad (Sómi)	Pan bread 47 g Salad 55 g	262	8
Oat biscuits (Frón) with butter, cheese and glass of milk (MS Dairies)	Oat biscuit 20 g Butter 10 g Cheese 20 g Milk 150 mL	342	12
Nutbar (Himneskt) with milk (MS Dairies)	Nutbar 40 g Milk 150 mL	302	10
Cheesecake (MS Dairies) – raspberry and chocolate	100 g	322	6
Mean		286	11

snacks themselves, for example, a whole cheesecake, because the minimal available pack size was more than one portion.

Verbal advice on the use of each intervention was also given to both groups, for example, ONS should be used from the fridge and snacks with less expiry date should be used first.

All patients could phone the study investigator if they needed more ONS or snacks, and every month each patient received a call to ascertain the quantity remaining. If patients were admitted to hospital during the study period they received ONS or snacks according to randomisation during their hospital stay.

During every follow-up appointment and during any hospital readmissions similar time was spent with each group.

Outcomes

Outcomes related to feasibility were percentage of eligible subjects that accepted participation (recruitment), percentage of included subjects that finished

the 12-month intervention period (retention), the feasibility of undertaking functional assessment and use of ONS/snacks assessed by 24-hour recalls (compliance).

The primary outcome was efficacy of the interventions assessed as weight change from baseline to 1 year from admission to the hospital. Assessment of body composition, that is, fat mass (FM), fat-free mass (FFM) and muscle mass, was conducted using a portable, multi-frequency (20 kHz, 100 kHz) bioelectrical impedance analysis device (InBody230, Korea). The method has previously been validated in patients with stable COPD.⁵

The secondary outcome measures were QoL measured using the St George's Respiratory Questionnaire (SGRQ). This validated questionnaire is based on 76 items used to calculate three component scores: symptoms, activity and impact, and a total score. A score of 100 represents worst possible health status and a score of 0 represents best possible health status.¹⁷ A change of 4 points in the SGRQ total score is considered the minimum clinically relevant difference.¹⁸

Other outcome measures included were forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) measured by spirometry (Jaeger MS-PFT, Care Fusion, San Diego, USA).¹⁹ Functional performance using several tests validated in patients with COPD were included: 6 min walk distance (6MWD),²⁰ timed up and go (TUG),²¹ 30 s chair stand²² and hand grip strength (HGS)²³ measured by a handheld dynamometer (Jamar Sammons Preston Rolyan, Bolingbrook, IL, USA), and energy and protein intake during hospital stay and at home (2 and 4 weeks after discharge).

Total energy and protein intake during hospital stay was estimated using a validated plate diagram sheet^{24 25} for 3 days, starting on the first day of participation in the study and after the intervention had started.

Energy and protein intake at home was assessed using the 24-hour recall method,²⁶ 2 and 4 weeks after hospital discharge, and analysed using the ICEFOOD nutritional analysis programme.²⁷ For full details of study assessments, see online supplementary appendix 1.

Statistical analysis

All statistical analyses were undertaken using IBM SPSS Statistics V.24 and the level of significance was set at 0.05.

Our original power calculations were based on the primary outcome of difference in weight gain between the groups and change in weight to 1 year. Due to low recruitment rate and lower participation rates than expected, post hoc power calculations were performed based on our results.

The Kolmogorov-Smirnov test was used to test data normality. The independent t-test was used to test for differences between continuous data at baseline and the Pearson's χ^2 test was used for categorical data. Intention-to-treat analyses were conducted where the last observations were carried forward and used to assess treatment efficacy. All patients with at least two measures (baseline and one other) were included. Repeated measures analysis of covariance was conducted to analyse mean changes in each follow-up.

RESULTS

Feasibility

A total of 492 COPD subjects were screened for nutritional risk in the Department of Pulmonary Medicine at Landspítali from September 2014 to December 2016. A total of 145 (30%) were identified at nutritional risk (score ≥ 4).

Recruitment and retention in the study

Thirty-four (45%) of the 76 eligible patients consented to take part in the study, 19 were randomised to the ONS group and 15 to the Snacks group. A total of 42 (55%) refused to participate (figure 1). Those who

refused to participate were significantly heavier than those who participated (61.9 kg vs 51.4 kg, $p < 0.001$) and had higher BMI (21.8 kg/m² vs 18.6 kg/m², $p < 0.001$). Of those 42 subjects who refused to participate, 6 (14%) were afraid of gaining weight, 3 (7%) did not like using ONS or snacks, 14 (33%) found the demands of the study quite heavy considering their clinical condition, 5 (12%) had practical issues with coming to clinic, 4 (10%) were already participating in another study outside the pulmonary unit and were unwilling to participate in two studies and 10 (24%) gave no reason for their refusal.

Twenty-three (68%) of 34 participants completed the 12-month study period. The proportion was similar in each group (figure 1). Of the 11 patients who did not complete the study, two withdrew due to illness and seven died. One repeatedly cancelled appointments and one was unable to be contacted. Three patients were readmitted within the first 30 days of the study ($n=2$ in the ONS group and $n=1$ in the Snacks group). There was no difference in cumulative LOS over 12 months between groups (median 40 days (95% CI 14 to 82) in the ONS group and median 46 days (95% CI 9 to 73) in the Snacks group). The total number of admissions to the hospital over the 12 months was 24 in the ONS group and 22 in the Snacks group. Compliance with both interventions in the early postdischarge period was either adequate (2–3 ONS/snacks per day) or greater than recommended (≥ 4 ONS/snacks per day).

Feasibility of undertaking functional assessments

The lowest retention rate was in the 6MWD with 12 (35%) patients completing the assessment at 12 months of follow-up, $n=15$ (44%) completed the TUG, $n=15$ (44%) 30 s chair stand and $n=19$ (56%) HGS. The most common reasons for not completing the functional tests were weakness, dyspnoea and fatigue.

Efficacy

Table 2 shows the baseline characteristics of the subjects.

Change in weight and body composition

Both groups tended to increase in body weight from baseline to 12 months (table 3). Mean per cent weight change from baseline to 12 months is shown in figure 2. We are not able to compare the difference between groups as a sample size of 176 subjects (88 subjects in each group) would have been needed to detect a difference of 2 kg in weight gain between the groups over 12 months period (statistical power of 0.8 and a p value of 0.05).

A significant increase in FM was seen in both groups. While there was a tendency towards decreased FFM from baseline to 12 months in the ONS groups, participants in the Snacks groups seemed to preserve their

Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. Study flow chart. ONS, oral nutritional supplements.

FFM. However, changes in FFM from baseline to 12 months were not statistically significant (table 3).

Weight loss from baseline to 12 months was observed in 7 (24%) patients (n=5 in ONS and n=2 in the Snacks group). Participants who lost weight were significantly older than those who gained weight (77 (8.7) years vs 69 (6.7) years, $p=0.006$). There was a tendency towards higher BMI at baseline in those who lost weight compared with those who were weight stable or gained weight (20.5 (3.2) kg/m^2 vs 17.8 (3.0) kg/m^2 , $p=0.054$), but no significant difference was seen in other variables, for example, smoking status, occupation and QoL.

Change in QoL

SGRQ total score significantly improved from baseline to 3 months in both groups (table 4). This improvement

was maintained at 12 months in the Snacks group (score improved by 8.9 (14.1) points, $p=0.041$); however, QoL declined in the ONS group as the study progressed resulting in no significant difference at 12 months (improvements by 3.9 (11.0) points, $p=0.176$). Improvement in SGRQ total score was mainly attributable to improvements in symptom scores.

Energy and protein intake

Total energy intake was significantly higher after hospital discharge than at baseline (in hospital) in both groups (figure 3). In the Snacks group, protein intake was significantly higher at 2–4 weeks after discharge than during hospitalisation (1.8 $\text{g}/\text{kg}/\text{day}$ vs 1.4 $\text{g}/\text{kg}/\text{day}$, respectively, $p=0.048$), while the increase in protein intake in

Table 2 Subjects' characteristics at baseline

	ONS n=19	Snacks n=15	P value*
Sex			
Male†	32	27	0.755
Female†	68	73	
Age (years)‡	72 (8)	73 (8)	0.852
Height (cm)‡	167 (11)	164 (10)	0.473
Weight (kg)‡	54 (10)	49 (10)	0.170
Body mass index (kg/m ²)‡	19.4 (4.1)	18.0 (2.7)	0.271
Body fat mass (kg)§	8.0 (3.3 to 16.2)	8.7 (3.2 to 10.1)	0.781
Fat-free mass (kg)‡	43.6 (10.5)	39.9 (8.5)	0.277
Fat-free mass index (kg/m ²)‡	13.0 (2.8)	12.1 (1.9)	0.280
Lung function			
FEV ₁ (% of predicted)‡	37.2 (16.3)	37.3 (9.5)	0.971
FVC (% of predicted)‡	64.7 (15.9)	66.9 (21.3)	0.726
Smoking status			
Smokers†	26	40	0.397
Ex-smokers†	63	60	
Non-smokers†	11	0	
Quality of life (SGRQ)			
Symptom score‡	65.1 (18.1)	62.6 (20.8)	0.716
Activity score‡	76.5 (29.1)	73.0 (17.1)	0.690
Impact score‡	54.6 (22.9)	46.4 (19.1)	0.290
Total score‡	63.2 (21.1)	57.2 (16.5)	0.391
Nutritional risk			
Score 4–5†	26	27	0.990
Score 6–7†	26	27	
Score 8–9†	42	40	
Score ≥10†	6	6	
6MWD (m)‡	234 (108)	185 (90)	0.194
HGS (kg)‡	15 (8)	14 (7)	0.785
TUG (s)§	15.6 (9.7 to 19.8)	15.0 (11.4 to 17.8)	0.841
30 s chair stand (n)‡	3.7 (4.0)	5.6 (3.0)	0.160
In-hospital physiotherapy†	58	67	0.424

*P value for independent t-test for continuous data (age, height, weight, body mass index, fat-free mass, fat-free mass index, FEV₁, FVC, SGRQ scores, 6MWD, HGS and 30 s chair stand), Mann-Whitney test for non-parametric data (body fat mass and TUG) and Pearson's χ^2 test for categorical data (gender, smoking status, nutritional risk score and in-hospital physiotherapy). †Data shown as %.

‡Data shown as mean (SD).

§Data shown as median (95% CI).

FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; HGS, hand grip strength; 6MWD, six min walking distance; ONS, oral nutritional supplements; SGRQ, St George's Respiratory Questionnaire; TUG, timed up and go.

the ONS group was not statistically significant (1.4 g/kg/day vs 1.2 g/kg/day, $p=0.213$).

Change in lung function, functional measures and muscle strength

No significant changes in lung function (FEV₁ and FVC) were seen between baseline and 12 months in either group. Similarly, functional measures and muscle

strength remained stable from baseline to 12 months in both groups (see online supplementary table 1).

DISCUSSION

Feasibility

Recruitment and retention in the study

In our study, more than half the eligible participants (55%) refused to take part and one-third of them found the demands of the study burdensome considering their clinical condition. Although similar participation rates have been seen in other nutritional intervention studies in patients with COPD,^{28 29} it can be speculated that in a study of such long duration and with as many follow-up visits, including tests related to physical function, recruiting patients from outpatient clinics might be more feasible than recruiting patients with exacerbations of disease in the hospital setting.

The retention rate after the 12-month intervention period was 68% and was similar for both groups. The most common reasons for not attending follow-up visits were weakness and length of the visits. Seven patients passed away and two withdrew due to the heavy burden of study assessments. A similar retention rate was seen in a study by Weekes *et al* with 56% of the participants completing the study.²⁸

Feasibility of undertaking functional assessments

The number of outcomes measured in the present study was extensive. Giving the challenges in getting people to attend follow-up visits and therefore the number of participants on whom data were gathered, the number of outcome measures should be minimised and assessments planned to be undertaken in the patient's home to prevent excessive participant burden in future studies. Furthermore, there were difficulties in measuring some of the secondary outcomes in those who attended follow-up visits. The reasons might be that majority of our study group (88%) had severe or very severe disease at baseline and as the study continued deterioration in clinical condition was seen in part of the study population.

Efficacy

Change in weight and body composition

A weight gain of more than 2 kg has been shown to be a significant predictor of survival in depleted and non-depleted patients with COPD.³⁰ In our study, both groups gained weight from baseline to 12 months. While the Snacks group tended to gain more weight than the ONS group (4.4 (6.4) kg ($p=0.030$) and 2.3 (4.6) kg ($p=0.060$), respectively), we do not have statistical power to detect significant difference between groups.

Significant weight gain in favour of supplementation and significant change from baseline in FFM and FM were seen among patients with COPD in a systematic review by Ferreira *et al*.¹¹ However, only three of the included studies assessed changes in FFM in undernourished patients and in all those studies nutritional support was combined with

Table 3 Mean change (SD) (kg) in body composition from baseline to each follow-up

	ONS				Snacks			
	3 months	6 months	9 months	12 months	3 months	6 months	9 months	12 months
Weight (kg)	2.1 (4.3)	2.2 (4.7)	2.1 (4.5)	2.3 (4.6)	2.7 (4.4)*	3.6 (5.3)*	3.4 (6.4)	4.4 (6.4)*
Fat mass (kg)	4.4 (6.4)*	3.9 (5.4)*	4.0 (5.0)*	3.7 (4.9)*	3.2 (4.5)*	2.8 (3.7)*	3.1 (4.8)*	2.9 (4.8)
Fat-free mass (kg)	-2.3 (5.4)	-1.7 (5.5)	-1.9 (6.0)	-1.3 (5.8)	-0.1 (3.3)	2.0 (6.0)	0.8 (6.3)	1.8 (6.1)
Fat-free mass index (kg/m ²)	-0.7 (1.6)	-0.5 (1.7)	-0.6 (1.8)	-0.4 (1.7)	0.0 (0.9)	0.5 (1.6)	0.1 (1.8)	0.5 (1.7)
Total body water (kg)	-1.5 (3.8)	-1.1 (3.8)	-1.3 (4.2)	-0.8 (4.1)	-0.1 (1.6)	1.3 (3.9)	0.4 (4.1)	1.1 (4.0)

Data shown as mean (SD). Intention-to-treat analysis. Groups: ONS (n=16), Snacks (n=13).

ONS, oral nutritional supplements.

*Significantly different from baseline, $p < 0.05$.

an exercise rehabilitation programme.^{31–33} In the study by Weekes *et al*, the intervention group maintained muscle mass and increased FM while in the control group both muscle mass and FM declined. None of their patients were undertaking pulmonary rehabilitation at the time.²⁸ In our study, there was an increase in FM in both groups. However, only participants in the Snacks group tended to increase FFM over time while there was a tendency towards a decrease in the ONS group. One reason might be higher protein intake/kg/day in the Snacks group, with an estimated protein intake of 1.8 g/kg/day 2–4 weeks after discharge from the hospital compared with 1.4 g/kg/day in the ONS group. Unfortunately, we do not have estimates of protein intake later in the study period. In contrast to our study, a study by Collins *et al* found protein intake after 3 months was higher in the group receiving ONS compared with the group receiving dietary advice although they did not assess FFM.²⁹

Quality of life

In the present study, QoL improved significantly from baseline to 3 months in both groups, however, only the Snacks group maintained the improvement at 12 months (improvements of 3.9 points in the ONS group and 8.9

points in the Snacks group). This is important since a change of 4 points in SGRQ total score is considered a minimum clinically relevant difference.¹⁸ Other studies have shown that nutritional intervention does appear to have an impact; however, the size of the effect varies between studies, perhaps due to the timing of the intervention, for example, in hospital or several months later, whether or not they were receiving pulmonary rehabilitation, and so on.^{28 32}

It is a strength that this is one of the longest nutrition intervention studies reported in patients with COPD, where other studies mostly using ONS tended to last for 3–6 months.^{9–11} However, information on what happened after intervention in our study is lacking. The Snacks group might continue to consume food similar to what was provided in the study as they are ordinary foods which can be bought in a grocery store. However, the ONS group might not unless ONS are subsidised from the health insurance.

To our knowledge, only one study in muscle-wasted patients with COPD had longer follow-up than ours (24 months), with nutritional intervention only for 4 months.³² Significant increase in BMI (1.1 (SE 0.37) kg/m²) was seen from baseline to 24 months of follow-up

Figure 2 Mean weight change (%) from baseline. Intention-to-treat analysis. Groups: ONS, oral nutritional supplements (n=16), Snacks (n=13).

Table 4 Quality of life (SGRQ)

	ONS			Snacks		
	Baseline	3 months	12 months	Baseline	3 months	12 months
Activity score	75.0 (30.5)	71.4 (30.2)	78.3 (21.3)	71.5 (16.8)	68.8 (18.8)	68.1 (15.9)
Impact score	52.8 (23.6)	44.2 (29.3)	48.5 (25.2)	45.7 (19.8)	35.9 (24.2)	35.5 (24.9)
Symptoms score	66.7 (16.9)	45.9 (19.4)*	51.1 (19.3)*	64.3 (20.7)	39.5 (23.0)*	49.0 (26.8)*
Total score	62.0 (22.1)	52.9 (26.8)*	58.1 (21.1)	56.7 (17.0)	46.6 (20.4)*	47.7 (20.7)*

Intention-to-treat analysis. Groups: ONS (n=16), Snacks (n=13).

Data shown as mean (SD).

ONS, oral nutritional supplements; SGRQ, St George's Respiratory Questionnaire.

*Significantly different from baseline, $p < 0.05$.

($p < 0.01$) compared with an increase of 0.8 (SE 0.42) kg/m^2 ($p = 0.079$) and 1.5 (SE 0.65) kg/m^2 ($p = 0.040$) in our ONS and Snacks groups, respectively. Similar to our study, weight increased rapidly in the first months, however in their study it remained stable after intervention. Our participants might have continued to gain weight if the intervention had been provided for a longer duration.

Although weight remained stable despite no further weight gain being achieved, it is important to highlight that in the majority of our patients, weight loss, which is associated with a higher mortality, was prevented.^{15 34}

It is a limitation that we only assessed compliance with two 24-hour recalls early in the follow-up period. Future studies should formally assess compliance in

Figure 3 (A) Energy and (B) protein intake/day during hospitalisation and in follow-up. Total energy and protein intake per kg actual body weight at baseline, during hospitalisation versus follow-up. ONS: 28 kcal v 39 kcal, $p = 0.002$ and 1.2 g vs 1.4 g, $p = 0.213$. Snacks: 32 kcal vs 40 kcal, $p = 0.009$ and 1.4 g vs 1.8 g, $p = 0.048$. ONS, oral nutritional supplements.

the longer term. It can be speculated that long-term supplementation is associated with reduced compliance; however, in a systematic review by Hubbard and colleagues, no relationship was seen between duration of ONS prescription and compliance.³⁵ Although some of our patients had previously been advised to take ONS, that is, recently or a few years previously, no patients had previously been provided with snacks. The quantity of the products provided throughout the study period, and gradual weight gain in the subjects up to 12 months after discharge suggests adequate or good compliance in the longer term in both groups.

Another limitation is that although positive results were observed in the main outcomes on our study, our sample size lacked power to be able to detect a significant difference between the two interventions in these outcomes. Also, the lack of control group receiving no intervention might be considered as a limitation, but given the results from previous studies we did not find it ethical not providing intervention in this high-risk group.

There are also some practical issues related to the approach tested in this trial. Although both interventions were provided free of charge in our study, this is not the case in clinical practice. ONS are partly subsidised or provided free of charge to malnourished individuals in many countries, but general food (snack) is not. Furthermore, the concept of our interventions has not been economically evaluated. Although each snack was cheaper than ONS, the expiry date was shorter and therefore the more regular delivery of the snacks might lead to greater expense.

Results from this feasibility study suggest that the provision of both ONS and snacks to patients with COPD is feasible on hospital discharge; however, future trials should be informed of the recruitment and retention issues that have been raised, and the use of functional tests as outcome measures in this population merits further consideration. Furthermore, future studies should include a formal health economic analysis since the cost-effectiveness of the two interventions may not be the same.

Author affiliations

¹Unit for Nutrition Research, Landspítali University Hospital and Faculty of Food Science and Nutrition, University of Iceland, Reykjavik, Iceland

²Department of Clinical Nutrition, Landspítali University Hospital, Reykjavik, Iceland

³Faculty of Health, Copenhagen University College, Copenhagen, Denmark

⁴Research Unit for Nutrition, Herlev and Gentofte Hospital, Copenhagen, Denmark

⁵Department of Nutritional Sciences, King's College London, London, UK

⁶The Icelandic Gerontological Research Institute, Landspítali University Hospital and University of Iceland, Reykjavik, Iceland

⁷Faculty of Medicine, University of Iceland, Reykjavik, Iceland

⁸Department of Sleep, Landspítali University Hospital, Reykjavik, Iceland

Acknowledgements Acknowledgement to the staff at the thoracic ward and the thoracic outpatient's clinic at Landspítali National University Hospital, Reykjavik, Iceland, and Eva Björg Björgvinsdóttir for her contribution to the data collection.

Contributors Concept and design of study: ARI, IG, AMB, CB, AR, TG and OGG. Data collection and data management: ARI. Analysing and interpretation of data:

ARI, IG, AMB, CB, CEW, AR, TG and OGG. Writing the manuscript: ARI. All authors participated in editing and final revisions of the manuscript. All authors have read and approved the final manuscript.

Funding This paper presents independent research that was supported by the Icelandic Research Fund of the Icelandic Centre for Research (141216-051), the Eimskip University Fund and the Landspítali University Hospital Research Fund. Oral nutritional supplements were partly funded by Nutricia (Iceland) and between meals by MS Iceland Dairies (Mjólkursamsalan).

Disclaimer The views expressed in this study are those of the authors and not necessarily those of the funding source.

Competing interests None declared.

Patient consent for publication Obtained.

Ethics approval The study was approved by the National Bioethics Committee (VSN14-066-S1), Chief Medical Officer Landspítali (LSH 68-14) and Data Protection Authority (2014/908).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0>

REFERENCES

1. Vermeeren MAP, Creutzberg EC, Schols AMWJ, *et al*. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. *Respir Med* 2006;100:1349–55.
2. Hogan D, Lan LTT, Diep DTN, *et al*. Nutritional status of Vietnamese outpatients with chronic obstructive pulmonary disease. *J Hum Nutr Diet* 2017;30:83–9.
3. Thorsdóttir I, Gunnarsdóttir I, Eriksen B. Screening method evaluated by nutritional status measurements can be used to detect malnourishment in chronic obstructive pulmonary disease. *J Am Diet Assoc* 2001;101:648–54.
4. Luo Y, Zhou L, Li Y, *et al*. Fat-free mass index for evaluating the nutritional status and disease severity in COPD. *Respir Care* 2016;61:680–8.
5. Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, *et al*. Body composition and mortality in chronic obstructive pulmonary disease. *Am J Clin Nutr* 2005;82:53–9.
6. Slinde F, Grönberg A, Engström C-P, *et al*. Body composition by bioelectrical impedance predicts mortality in chronic obstructive pulmonary disease patients. *Respir Med* 2005;99:1004–9.
7. Hallin R, Gudmundsson G, Suppli Ulrik C, *et al*. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). *Respir Med* 2007;101:1954–60.
8. Hoong JM, Ferguson M, Hukins C, *et al*. Economic and operational burden associated with malnutrition in chronic obstructive pulmonary disease. *Clin Nutr* 2017;36:1105–1109.
9. Collins PF, Elia M, Stratton RJ. Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Respirology* 2013;18:616–29.
10. Collins PF, Stratton RJ, Elia M. Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Am J Clin Nutr* 2012;95:1385–95.
11. Ferreira IM, Brooks D, White J, *et al*. Nutritional supplementation for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012;12:CD000998.
12. Tróbal J, Farran-Codina A. Effects of dietary enrichment with conventional foods on energy and protein intake in older adults: a systematic review. *Nutr Rev* 2015;73:624–33.
13. Morilla-Herrera JC, Martín-Santos FJ, Caro-Bautista J, *et al*. Effectiveness of food-based fortification in older people: a systematic review and meta-analysis. *J Nutr Health Aging* 2016;20:178–84.
14. Eldridge SM, Chan CL, Campbell MJ, *et al*. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *Pilot Feasibility Stud* 2016;2:64.
15. Ingadóttir AR, Beck AM, Baldwin C, *et al*. Two components of the new ESPEN diagnostic criteria for malnutrition are independent predictors of lung function in hospitalized patients with chronic obstructive pulmonary disease (COPD). *Clin Nutr* 2018;37:1323–1331.

16. Friðriksdóttir AJ, Möller PH, 2011. Clinical guidelines on patients nutrition: Landspítali. Available from: <http://www.landspitali.is/lisalib/getfile.aspx?itemid=28242> [Accessed 19 Sep 2012].
17. Jones PW, Quirk FH, Baveystock CM, *et al.* A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis* 1992;145:1321–7.
18. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. *Eur Respir J* 2002;19:398–404.
19. Vogelmeier CF, Criner GJ, Martinez FJ, *et al.* Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med* 2017;195:557–82.
20. Singh SJ, Puhan MA, Andrianopoulos V, *et al.* An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. *Eur Respir J* 2014;44:1447–78.
21. Mesquita R, Wilke S, Smid DE, *et al.* Measurement properties of the Timed Up & Go test in patients with COPD. *Chron Respir Dis* 2016;13:344–52.
22. Kato D, Fueki M, Endo Y, *et al.* 30-second chair-stand test is a valuable evaluation in chronic respiratory diseases. *Eur Respir J* 2014;44(Suppl 58).
23. Puhan MA, Siebeling L, Zoller M, *et al.* Simple functional performance tests and mortality in COPD. *Eur Respir J* 2013;42:956–63.
24. Björnsdóttir R, Oskarsdóttir ES, Thordardóttir FR, *et al.* Validation of a plate diagram sheet for estimation of energy and protein intake in hospitalized patients. *Clin Nutr* 2013;32:746–51.
25. Vilhjálmsson DÖ, Hinriksdóttir HH, Þórdardóttir FR, *et al.* [Energy and protein intake of patients at the Department of Cardiothoracic surgery, Landspítali - the National University Hospital of Iceland]. *Laeknabladid* 2013;99:71–5.
26. Salvador Castell G, Serra-Majem L, Ribas-Barba L. What and how much do we eat? 24-hour dietary recall method. *Nutr Hosp* 2015;31(Suppl 3):46–8.
27. Þorgeirsdóttir H, Valgeirsdóttir H, Gunnarsdóttir I, *et al.* Hvað borða Íslendingar? Könnun á mataræði Íslendinga 2010–2011. *Helstu niðurstöður: Embætti Landlæknis, Matvælastofnun and Rannsóknastofa í næringarfræði* 2011.
28. Weekes CE, Emery PW, Elia M. Dietary counselling and food fortification in stable COPD: a randomised trial. *Thorax* 2009;64:326–31.
29. Collins PF, Stratton RJ, Elia M. PP122-SUN: Outstanding abstract: Nutritional support in Chronic Obstructive Pulmonary Disease (COPD): A Randomised Trial. *Clin Nutr* 2014;33:S65.
30. Schols AM, Slangen J, Volovics L, *et al.* Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;157:1791–7.
31. Sugawara K, Takahashi H, Kasai C, *et al.* Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD. *Respir Med* 2010;104:1883–9.
32. van Wetering CR, Hoogendoorn M, Broekhuizen R, *et al.* Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. *J Am Med Dir Assoc* 2010;11:179–87.
33. Schols AM, Soeters PB, Mostert R, *et al.* Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. *Am J Respir Crit Care Med* 1995;152:1268–74.
34. Prescott E, Almdal T, Mikkelsen KL, *et al.* Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. *Eur Respir J* 2002;20:539–44.
35. Hubbard GP, Elia M, Holdaway A, *et al.* A systematic review of compliance to oral nutritional supplements. *Clin Nutr* 2012;31:293–312.